This is an Open Access article licensed under the terms of the Creative Commons AttributionNonCommercial 3.0 Unported license (CC BY-NC) (www.karger.com/OA-license), applicable to the online version of the article only. Distribution permitted for non-commercial purposes only. cardiomyocytes (CMs) is essential for their use in regenerative medicine, drug testing and disease modeling. The aim of this study was to evaluate the effect of some previously reported cardiogenic substances on cardiac differentiation of mouse PSCs. Methods: Differentiation was performed by embryoid body (EB)-based method using three different murine PSC lines. T cytometry, and the effect mechanistically evaluated by transcriptome analysis of treated EBs.
Introduction
Cardiovascular diseases are the most frequent cause of death in adults and main noninfectious cause of death in children in the United States and Western Europe [1] . Due to the limited capacity of adult cardiomyocytes (CMs) to proliferate, cell losses of failing heart are irreversible and strategies for replacement of damaged cells by various types of exogenous cells are being developed [2, 3] . Pluripotent stem cells (PSCs) such as embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs), represent an attractive source of clinically useful CMs because they are easily accessible and expandable in culture, have broad developmental potential and high capacity to reproducibly differentiate into spontaneously beating cardiac cells in vitro to bypass immunologic complications and ethical concerns that complicate the clinical term behavior of iPSC-derived grafts. Major effort of many investigators in recent years has been to develop methods for enrichment of stem cell-derived CMs in vitro in order to such as the Gsk3 inhibitors CHIR99021 and , inhibitor of Wnt response-1 (IWR1), inhibitor of Wnt production-4 (IWP4) inhibitor of BMP signaling dorsomorphin and ascorbic acid [7] [8] [9] [10] [11] [12] [13] [14] [15] .
yield of CMs is the major obstacle for use of PSCs in developmental studies, in vitro disease modeling and tissue repair. Thus, it is required to compare and validate cardiogenic potential improve the CM yield, homogeneity, maturation and functionality.
(ascorbic acid, dorsomorphin, cyclic adenosine 3',5'-monophosphate, cardiogenol C and cyclosporin A) differentiation to better understand the mechanism of AA-induced cardiac differentiation.
non-treated cells despite pronounced enhancement of CM yield in AA-treated group in later stages of differentiation. Most up-regulated transcripts on days 2 and 5 of differentiation addition of QS11, a small molecule synergist of Wnt/ the combined application of AA and QS11 resulted in a more consistent induction of CM differentiation from all three tested murine PSC lines than each substance alone, although batch-to-batch variability in CM yield could not be completely eliminated. These data indicate that variable cardiogenic potential of different PSCs and response to effective small molecules can be diminished but not completely abolished by a combination of different inducers of cardiogenesis that target different cellular processes at different stages of differentiation. 
Results

all attached EBs on gelatin-coated dishes to initially estimate the cardiac enhancing potential
Actn2, Tnnt2 and
respectively. These data demonstrate that the observed increase in the number of beating MHC to differentiation [24, 25, [34] [35] [36] .
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PIG44 and AT25
PIG44 ESCs (Fig. 3B ). In treated and untreated EBs on day 2 and 3 of differentiation and that only 9 unique tran--pressed on day 5 of differentiation (Fig. 4C) . In contrast, in and untreated EBs on day 2, day 3 and day 5 of differentiation, -dily increasing developmental ESCs and differentiating EB cell populations (Fig. 4C) genes after stringent statistical -lysis by considering probe sets expression change higher than 1.5-fold -covery rate. Under this condiand untreated day 2 EBs of ) and hematopoiesis/erythropoiesis ( and the early mesodermal markerT-brachyury 6 and 7). The expression levels of selected genes ( ) analysis (Fig. 4E, F (Fig. 5C,D) differentiation days 0-9 or 0-2 (Fig. 6A-C) , indicating that its variable (Fig. 5C-F and 6A,B) and the basal differentiation the inherent instability in cardiac differentiation of AT25 (Fig. 5E ). These data indicate that cardiogenic potential of some PSC lines can be enhanced by small molecules but batchto-batch variability in CM yield cannot be completely abolished by combined application of AA and QS11 or by each drug alone. Table 6 . Gene ontology analysis of genes UP-regulated in ascorbic acid-treated day 2 EBs and day 5 EBs. Processes found to be induced by AA are presented for categories: biological processes (BP), molecular funthreshold of at least 3 gene counts. The percentage indicates the number of genes involved in the respective -log2-transformed value) in angiogenesis, hematopoiesis and vasculature development. Increasing our understanding of the mechanism of action of cardiogenic compounds and combined use of small molecules therapeutic applications in regenerative medicine.
